Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study

Conclusion: Our study found irinotecan and capecitabine administered fortnightly with bevacizumab in patients with mCRC to be an effective and tolerable regimen.Trial registrationclinicaltrials.gov identifier NCT00875771. Trial registration date: 04/02/2009.

http://www.biomedcentral.com/1471-2407/15/327

Source: Epidemiologic Perspectives and Innovations - April 28, 2015 Category: Epidemiology Authors: Pilar Garcia-AlfonsoManuel ChavesAndrés MuñozAntonieta SaludMaria García-GonzalezCristina GrávalosBartomeu MassutiEncarna González-FloresBernardo QueraltAmelia López-LadrónFerran LosaMaria GómezAmparo OltraEnrique Arandaon behalf of the Spanish Co Source Type: research